Arvind Dasari, MD, MS, explains how to sequence radioligand therapy, cabozantinib, and everolimus in well-differentiated neuroendocrine tumors.
|Videos|October 3, 2017
The Therapeutic Management of Metastatic CRC
The Therapeutic Management of Metastatic CRC
Advertisement
November 2015
- A 62-year-old Caucasian female presents with severe crampy right lower quadrant pain
- 6-month history of occult bleeding and weight loss of 15 pounds in the last 8 months
- PMHx: tonsillectomy at age 23; hysterectomy at age 55
- FHx: Mother diagnosed with colon cancer at age 71
- Laboratory findings: remarkable for Hb, 7.6 g/dL; CEA 5.5 ng/mL
- Colonoscopy reveals a large mass in the ascending colon, measuring approximately 11 cm
- Biopsy results: Invasive, poorly differentiated adenocarcinoma
- Additional pathologic testing
- KRAS,NRAS, andBRAFwild-type
- Microsatellite stable
- CT scan revealed widespread lesions in the left lobe of the liver
- Performance status: 0
- Treatment was initiated with FOLFOX + bevacizumab
- The patient experienced mild neuropathy, significant mucositis, grade 4 neutropenia, and severe diarrhea with the first cycle (suspected DPD deficiency)
- She subsequently tolerated therapy well with 50% dose reduction of her regimen in addition to dropping the bolus 5-FU and leucovorin.
- Follow-up imaging showed reduction in the size of the liver lesions
- Patient is planned to start maintenance therapy with low-dose capecitabine plus bevacizumab after 8 cycles of FOLFOX
August 2016
- Follow-up CT showed progression in the liver with new lesions
- Performance status: 1
- She began therapy with mFOLFIRI + bevacizumab
- CEA levels stabilized
February 2017
- The patient complained of severe fatigue and additional weight loss. Her performance status remains at 1.
- CT scan revealed progressive disease with 2 new pulmonary nodules in the left lower lobe of the lung and mild progression in the liver.
Advertisement
Related to this article
A survey of US veterans with non-muscle invasive bladder cancer identifies barriers to treatment access, care coordination challenges, and gaps in patient education.
The perioperative regimen improved event-free and overall survival in the phase 3 VOLGA trial, offering a new option for patients with muscle-invasive bladder cancer who cannot receive or decline cisplatin.
Ravi Parikh, MD, MPP, discusses the future of oncology practice, including real-world data, patient engagement, emerging technologies, and policy priorities shaping cancer care.
Updated guidance recommends biennial prostate-specific antigen testing for average-risk men aged 50 to 69 years and annual screening beginning at age 45 for higher-risk men.
The NDA was completed for first-line zipalertinib plus platinum chemotherapy in EGFR exon 20 insertion NSCLC, based on phase 3 REZILIENT3 data showing improved PFS.
Telisotuzumab adizutecan showed promising survival in pretreated nonsquamous NSCLC, with the most benefit in EGFR wild-type tumors with high c-Met levels.
During a live event, Rushang Patel, MD, PhD, and participants discussed referral timing, bridging, and payer barriers that shape access to cellular therapy in early relapsed multiple myeloma.
Advertisement
Advertisement
Trending on Targeted Onc
1
FDA Approves Durvalumab-EV Combo, Expanding MIBC Treatment Options
2
Dr Dasari on Sequencing RLT, Cabozantinib, and Everolimus in NETs
3
New ACS Guidelines Push for Earlier Prostate Cancer Screening
4
Survey Highlights NMIBC Care Challenges Among US Military Service, Veterans
5